HR Positive/ HER2 Negative Breast Cancer Market

HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumor growth. A number of classes of anti estrogenic agents available for patients with early, advanced, or metastatic breast cancer includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.

HR Positive/ HER2 Negative Breast Cancer Market Key Facts
Among the 7MM, the US accounts for the 80.51% USD of the overall market size of ER-positive/HER2-negative Breast Cancer in 2017.
The most incident cases of ER+/HER– breast cancer were recorded in the United States.
The lowest incident population of ER+/HER– breast cancer was recorded in Japan.
Among the EU5 countries, Germany accounts for the highest market size for ER-positive/HER2-negative Breast Cancer followed by France, Italy, the UK, and Spain.

For more details visit:
https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights